Carcinoma de células escamosas del pene · línea 1 · Pembrolizumab en monoterapia (MSI-H mCRC 1L)

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

Registro de base de conocimiento para la auditoría. Contenido clínico provisional: esto no es una prescripción. Un oncólogo debe verificar fuentes originales, aplicabilidad y estado de revisión.

Fuente YAML: registro completo

Línea de tratamiento	1
Track	agresivo
Régimen vinculado	`REG-PEMBROLIZUMAB-MSI-MONO`

ID	`IND-PENILE-SCC-METASTATIC-1L-MSI-H-PEMBRO`
Tipo	Indicación
Situación	reviewed 2026-07-11 \| pending_clinical_signoff
Enfermedades	`DIS-PENILE-SCC`
Fuentes	`SRC-EAU-PENILE-2024`

Notas

STUB — bonus/4th indication beyond the 3 explicitly requested in this authoring pass, added because the DIS-PENILE-SCC narrative explicitly names "pembrolizumab in MSI-H subset" and nearly every referenced entity already exists in the KB (DRUG-PEMBROLIZUMAB, REG-PEMBROLIZUMAB-MSI-MONO, BIO-MSI-STATUS, CI-PEMBROLIZUMAB-AUTOIMMUNE, RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK) — low-invention-risk, high narrative fidelity. New RF-PENILE-SCC-MSI-H-ACTIONABILITY authored to gate this branch in ALGO-PENILE-SCC-1L. Independent review removed a proposed secondary citation to SRC-NCCN-BLADDER-2025 (that source is the NCCN Bladder Cancer guideline, relates_to_diseases: [DIS-UROTHELIAL] only — it does not cover penile cancer and should not be cited here; SRC-EAU-PENILE-2024 alone supports this indication). Requires medical-oncology co-lead signoff before clinical publication (CHARTER §6.1; dev-mode-exempted for draft merge).

Utilizado por

Algoritmos

ALGO-PENILE-SCC-1L - ALGO-PENILE-SCC-1L

Indicación

IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU - IND-PENILE-SCC-METASTATIC-1L-CISPLATIN-5FU
IND-PENILE-SCC-METASTATIC-1L-TIP - IND-PENILE-SCC-METASTATIC-1L-TIP